Vepdegestrant
| Clinical data | |
|---|---|
| Pronunciation | /ˌvɛpdəˈdʒɛstrənt/ VEP-də-JES-trənt |
| Trade names | Veppanu |
| Other names | ARV-471 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a626067 |
| License data | |
| Routes of administration | By mouth |
| Drug class | Estrogen receptor antagonist |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C45H49N5O4 |
| Molar mass | 723.918 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Vepdegestrant, sold under the brand name Veppanu, is an anti-cancer medication used for the treatment of breast cancer. It is a heterobifunctional protein degrader. It was developed by Arvinas and Pfizer. It is taken by mouth.
Vepdegestrant was approved for medical use in the United States in May 2026.
Category:
- Drugs not assigned an ATC code